EpiCast Report: Growth Hormone Deficiency - Epidemiology Market Forecast to 2026

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth (congenital), or it can be secondary due to brain trauma (acquired). Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. Patients who acquire GHD later in life present with more generalized symptoms, such as increased abdominal fat, decreased levels of energy, and decrease in muscle mass. In young children, certain kinds of cancer treatments, such as cranial radiation, can increase the chances of developing GHD. Other clinical procedures, such as brain surgery, can increase a patient’s chances of developing GHD. GHD may be hereditary, or it may be due to fetal malformation or genetic mutations. Acquired GHD can be caused by trauma to the head or brain and more commonly by a pituitary adenoma.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1142776

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26% in the 7MM. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13% of all cases of GHD in the 7MM.

This 10-year epidemiological forecast of GHD is supported by data obtained from international GHD disease monitoring databases, country-specific government sources, as well as peer reviewed studies using market-relevant disease definitions across the 7MM. This forecast provides detailed segmentations within GHD for each market by the patient’s age, sex, and etiological classification (congenital and idiopathic in children, and idiopathic and acquired in adults), thus creating a comprehensive view of the epidemiology of GHD in the 7MM. GlobalData epidemiologists maintained consistent forecast methodology across all seven markets, thus allowing for an accurate and meaningful comparison of included parameters among them.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1142776

Scope
• The Growth Hormone Deficiency (GHD) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.
• The GHD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The GHD EpiCast series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global GHD market.
• Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
• Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/epicast-report-growth-hormone-deficiency-epidemiology-forecast-to-2026-report.html

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.